Wai Lun Will Pak

Wai Lun Will Pak

Auto-generated profile, based on publicly available information

Wai Lun Will Pak

United Christian Hospital

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2021 in Nephrology
Verified
Journal Article
Open access
PDF file
MSMai Sugahara
Mai Sugahara
WPWai Lun Will Pak
Wai Lun Will Pak
TTTetsuhiro Tanaka
Tetsuhiro Tanaka
STSydney C. W. Tang
Sydney C. W. Tang
MNMasaomi Nangaku
Masaomi Nangaku
Diabetic kidney disease (DKD) is a chronic complication of diabetes mellitus which may eventually lead to end‐stage kidney disease (ESKD). Despite improvements in glycaemic control and blood pressure management with renin‐angiotensin‐aldosterone system (RAAS) blockade, the current therapy cannot completely halt DKD progression to ESKD in some patients. DKD is a heterogeneous disease entity in terms of its clinical manifestations, histopathology and the rate of progression, which makes it difficult to develop effective therapeutics. It was formerly considered that albuminuria preceded kidney function decline in DKD, but recent epidemiological studies revealed that a distinct group of patients presented kidney dysfunction without developing albuminuria. Other comorbidities, such as hypertension, obesity and gout, also affect the clinical course of DKD. The pathophysiology of DKD is complex and multifactorial, involving both metabolic and haemodynamic factors. These induce activation of intracellular signalling pathways, oxidative stress, hypoxia, dysregulated autophagy and epigenetic changes, which result in kidney inflammation and fibrosis. Recently, two groups of antidiabetic drugs, sodium‐glucose cotransporter 2 (SGLT2) inhibitors and glucagon‐like peptide‐1 (GLP‐1) receptor agonists, were demonstrated to provide renoprotection on top of their glucose‐lowering effects. Several other therapeutic agents are also being developed and evaluated in clinical trials.

15 June 2024 in Kidney Medicine
Verified
Journal Article
Open access
WPWai Lun Will Pak
Wai Lun Will Pak
NBNatalie A. Brumwell
Natalie A. Brumwell
CKCharlene C. Kabel
Charlene C. Kabel
VGVictoria Gutgarts
Victoria Gutgarts
ISInsara Jaffer Sathick
Insara Jaffer Sathick
ASAisha Shaikh
Aisha Shaikh
Chimeric antigen receptor (CAR) T-cell therapy against B-cell maturation antigen is a new treatment modality for relapsed or refractory multiple myeloma (MM). Patients with kidney failure and MM were excluded from the pivotal CAR T-cell therapy clinical trials: KaRMMa (idecabtagene vicleucel) and CARTITUDE (ciltacabtagene autocleucel). The safety and efficacy of CAR T-cell therapy in patients with relapsed or refractory MM and kidney failure are limited to a few case reports using idecabtagene vicleucel. Here, we report the first 2 cases of ciltacabtagene autoleucel use in patients with kidney failure on maintenance hemodialysis and relapsed or refractory MM. Both patients achieved a hematologic response following ciltacabtagene autoleucel administration without serious adverse events. These findings suggest that ciltacabtagene autoleucel may be safe and effective in patients with relapsed or refractory MM and kidney failure. In this report, we review the available literature regarding the use of CAR T-cell therapy in patients with MM and kidney failure. We also discuss the modification of the lymphodepletion regimen in the kidney failure setting.

27 January 2023 in Nephrology
Verified
Journal Article
Closed access
WPWai Lun Will Pak
Wai Lun Will Pak
KCKa Lok Chan
Ka Lok Chan
ZCZi Chan
Zi Chan
WLWai Ping Law
Wai Ping Law
YWYick Hei Wong
Yick Hei Wong
SWSze Ho Sunny Wong
Sze Ho Sunny Wong

23 March 2022 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Closed access
WPWai Lun Will Pak
Wai Lun Will Pak
KCKa Lok Chan
Ka Lok Chan
ZCZi Chan
Zi Chan
YWYick Hei Wong
Yick Hei Wong
WLWai Ping Law
Wai Ping Law
SWSze Ho Sunny Wong
Sze Ho Sunny Wong
Background: Peritoneal dialysis (PD) patients with impaired hand–eye function require helper assistance. Our centre developed a connection device that assists patients with impaired hand–eye function to perform PD exchange themselves, but the clinical outcomes in these patients have not been investigated. Methods: We retrospectively reviewed patients who had device-assisted continuous ambulatory peritoneal dialysis (CAPD) during 2007–2016 and compared their clinical outcomes with age- and sex-matched patients receiving helper-assisted CAPD. Results: One hundred seventy-two patients (86 each in the device- and helper-assisted CAPD groups) were followed for 29.9 (19.4–43.3) months. The device- and helper-assisted groups had comparable peritonitis rates (0.489 and 0.504 episode per patient-year, respectively, p = 0.814), with no difference in the distribution of causative organisms and the organism-specific peritonitis rates. The device-assisted group showed similar peritonitis-free survival compared with the helper-assisted group (2.58 (1.85–3.31) vs. 1.78 (0.68–2.88) years, p = 0.363) and time-to-PD discontinuation (6.27 (3.65–8.90) vs. 4.35 (3.48–5.22) years, p = 0.677). The median patient survival was similar between the two groups (3.89 (2.22–5.55) vs. 3.81 (3.27–4.36) years in the device- and helper-assisted groups, respectively, p = 0.505). Conclusion: Device-assisted CAPD confers comparable outcomes as helper-assisted CAPD and is a viable option in PD patients with impaired hand–eye function.

11 November 2021 in Nephrology
Verified
Journal Article
Closed access
PDF file
WPWai Lun Will Pak
Wai Lun Will Pak
KCKa Lok Chan
Ka Lok Chan
ZCZi Chan
Zi Chan
WLWai Ping Law
Wai Ping Law
YWYick Hei Wong
Yick Hei Wong
SWSze Ho Sunny Wong
Sze Ho Sunny Wong

2 September 2019 in Nephrology
Verified
Journal Article
Closed access
PDF file
WPWai Lun Will Pak
Wai Lun Will Pak
KCKa Lok Chan
Ka Lok Chan
ZCZi Chan
Zi Chan
WLWai Ping Law
Wai Ping Law
YWYick Hei Wong
Yick Hei Wong
SWSze Ho Sunny Wong
Sze Ho Sunny Wong